Latest Conference Articles

Full results from the pivotal B-Well 1 and B-Well 2 phase 3 trials confirm that bepirovirsen delivers statistically significant functional cure rates in chronic hepatitis B.

Two posters presented at the EASL Congress 2026 highlight promising clinical and preclinical findings for AHB-137.

The American Thoracic Society 2026 International Conference included sessions that focused on topics such as pulmonary rehabilitation and global disparities in thoracic care.

ATS 2026 showcased new pulmonary therapies, clinical trials, and cross-specialty collaboration to improve patient care.

Pharmacists need better support to manage emotional strain tied to patient suffering, treatment costs, and care decisions, says Karen Fancher, PharmD, BCOP.

Ontada research presented at ISPOR 2026 shows the NCCN Distress Thermometer can predict overall survival in metastatic cancers, but the relationship varies by cancer type.

Ontada finds that EHR-based education boosts NCCN guideline-concordant care for patients with HER2-low metastatic cancer, raising targeted treatment use among providers who took part in the education activities.

Jamie R. Felzer, MD, discusses vaccine misinformation, public mistrust, and strategies to restore confidence in this science.

Yet Khor, MD, PhD, discusses ILD care disparities, telehealth, trial awareness, and shared care strategies.

Jamie R. Felzer, MD, discussed emerging vaccine strategies, preventive care, and translating evolving evidence into pulmonary practice at ATS 2026.

Yet Khor, MD, PhD, highlights diagnostic delays, language barriers, and inequities impacting ILD and PF care access.

New data examine switching biologics in severe asthma and inhaled treprostinil's effect on lung function in idiopathic pulmonary fibrosis (IPF).

Poster data show the efficacy of nerandomilast in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis.

SUNRISE data showed tezepelumab improved asthma outcomes while reducing steroid dependence in severe asthma.

FVC percent predicted could differ in those with ILD who progress to terminal outcomes, indicating a need for patient monitoring.

Diana Verrilli, MS, of Navista breaks down the regulatory, payer, and cybersecurity pressures threatening community oncology practices—and maps a path forward.

Chad Hochberg, MD, discussed how ICU learning health systems and predictive tools may improve critical care delivery.

SUNRISE trial data showed tezepelumab reduced oral steroid use while maintaining asthma control in severe asthma.

New findings presented at ACC.26 highlight the potential of Lp(a)-targeted therapies for patients with ASVD and elevated Lp(a).

ALIS plus MDT improved symptoms and culture conversion in newly diagnosed MACLD, according to late-breaking data presented at ATS 2026.

PASSAGE trial data showed tezepelumab reduced asthma exacerbations in diverse and underrepresented patient populations, noted Njira L. Lugogo, MD.

ATS 2026 findings highlighted bleeding risks and hemodynamic responses with sotatercept in CTD-associated pulmonary arterial hypertension (PAH).

Early results show the potential for congestion pricing and clean air zones to be beneficial for the health of children in major cities.

RECOVER Initiative findings highlighted the heterogeneity of long COVID symptoms and mechanisms in diverse patient populations.

PASSAGE study data showed tezepelumab improved asthma outcomes across diverse, underrepresented patient populations.

Differences between sexes in cardiovascular health can appear as early as the neonatal stage in preterm infants.

Demetre Daskalakis, MD, MPH, Callen-Lorde, opened the first full day of ATS 2026 by highlighting the past, present, and future of vaccine policy in the US.